Skip to main
GRAL

GRAIL Inc (GRAL) Stock Forecast & Price Target

GRAIL Inc (GRAL) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 11%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

GRAIL is a leader in the multi-cancer early detection (MCED) market and has the potential to greatly reduce cancer mortality through its Galleri test. With its partnership with Epic and a growing sales force, GRAIL is establishing the infrastructure needed for widespread adoption. While the recent Q1 earnings beat was positive, investors will be keeping a close eye on the upcoming release of ASCO data and FDA approval for potential catalysts. Given the potential upside and the significant risks, this suggests a neutral position on the stock.

Bears say

GRAIL is facing a lack of stability and guidance clarity, with uncertainties in digital health partner uptake, sales force ramp, and the potential impact of the full NHS dataset at ASCO. While Q1 sales beat expectations, there is still a risk of FDA disapproval or Medicare non-reimbursement. However, with the stock trading at a low multiple and significant potential for positive catalysts, a Buy rating is justified with a 75% chance of FDA approval and 50% chance of Medicare coverage in the near future.

GRAIL Inc (GRAL) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 11% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRAIL Inc (GRAL) Forecast

Analysts have given GRAIL Inc (GRAL) a Buy based on their latest research and market trends.

According to 9 analysts, GRAIL Inc (GRAL) has a Buy consensus rating as of Sep 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $72.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $72.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRAIL Inc (GRAL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.